ONE STEP QUANTIFICATION ANALYTICAL METHOD AND CHARACTERIZATION OF VALSARTAN BY LC-MS


S. Udhayavani, V. Girija Sastry, R. Govinda Rajan, V. Ramya Krishna, J. K. D. Tejaswi

Abstract


Objective: To develop precise LC-MS method for the estimation of valsartan impurities and perform validation as per ICH guidelines.

Methods: Valsartan (VLN) and its degradation products were analyzed by reverse phase high - performance liquid chromatography (RP-HPLC) using mobile phase water: acetonitrile: glacial acetic acid: phosphate buffer in the ratio of 500:500:1:0.5 v/v/v/v at 225 nm using column nucleosil C18, 125 ×4.0 mm, 5 µm. VLN sample (VLN SPL) thus obtained an unknown major impurity (UIMP) of 0.5 % at 0.38 retention time ratio (RRt) and purity of VLN was found to be 98.70 % respectively.

Results: Estimation of VLN SPL total unknown impurities was found to be 1.3% by RP-HPLC. In similarly by liquid chromatography mass spectroscopy (LC-MS) a typical chromatogram of valsartan (VLN) at Rt 9.03 min and UIMP at Rt 3.3 min were recorded at a total run time of 23 min. Assay of VLN SPL was validated as per international council for harmonization (ICH) guidelines. Average %  recovery was found to be 100.04 % for VLN SPL.

Conclusion: The proposed work clearly indicates that the method can be easily adapted for the routine one step estimation of VLN active pharmaceutical ingredient (API).


Keywords


Valsartan, Acetonitrile, Methanol, LC-MS, Mobile Phase.

References


Nadeem S, et al Pharmacological and Pharmaceutical Profile of Valsartan: A Review J. Applied Pharmacy Sci., 2011 01 (04); 12-19.

Shankar R, et al Process for the preparation of angiotensin 2 receptor antagonist, USPC class: 548283, patent application Number: 20090281326, 2009.

Nandita P, et al API Scale-up during Research and Development, Pharmaceutical technology, electronic edition, Volume 1 (3), 2005, 5-7.

Ulrich B, A High-Throughput Process for the synthesis of Valsartan Intl. J. Res. pharmacy Chem., 2007, 11 (5), 892–898

ICH (International conferences on Harmonization), 2000, Draft Revised Guidance on Impurities in New Drug Products. Q3B(R). Federal Register. 65(139):44791-44797.

ICH (International conferences on Harmonization), Draft Revised Guidance on impurities in New Drug substances Q3A(R). Federal Register, 2002, 3-14.

N. Rama Rao, et. al, Pharmaceutical Impurities: An Overview, Indian J. Pharm. Educ. Res., 44(3), 2010, 301-310.

S. Lakshmana Prabu, Impurities and Its Importance in Pharmacy, Intl. J. Pharma. Sci. Rev. Res., Volume 3, Issue 2, 2010, 66-71.

Sanjay B. Bari, Impurity profile: Significance in Active Pharmaceutical Ingredient, Eurasian J. Anal. Chem., Volume 2, Number 1, 2007, 23-25.

Ch. Krishnaiah, Stability-indicating UPLC method for determination of Valsartan and their degradation products in active pharmaceutical ingredient and pharmaceutical dosage forms J. Pharmacy Biomed. Anal., 53(3), 2010, 83-489.

Kena H. Patel, et.al, Simultaneous Estimation of Sacubitril and Valsartan in Synthetic Mixture by RP-HPLC Method, J. Pharm. Sci. Bio scientific Res., 6(3), 2016, 262-269.

L.R.D.Bhavani and Durga aruna R, Method Development and Validation of HPLC for Determination of Levetiracetan and Valsartan in their Formulations, Research and Reviews: J. Pharma. Anal., Volume 4, Issue 2, 2015, 42-56.

Mittal A, et.al, Design of Experiment based Optimized RP-HPLC Method for Simultaneous Estimation of Amlodipine and Valsartan in Bulk and Tablet Formulations, Austin J. Anal. Pharma. Chem., Vol 2(6), 2015, 1-6.

Subhajit G, et.al, RP-HPLC Method for Estimation of Valsartan in Solid Oral Dosage Forms, J Pharma Sci. Tech., Volume 3 (2), 2014, 88-91.

Sridevi Ramachandran, et.al, Stability-Indicating HPLC Method for Simultaneous Determination of Valsartan and Ezetimibe in Pharmaceuticals, Trop. J Pharma. Res., 13 (5): 2014, 809-817.

Sampath A, et.al Identification and characterization of potential impurities of Valsartan, AT1 receptor antagonist, J. Pharmacy Biomed. Anal., volume 50(3), 2009, 405-12.

Surbhi Mehta, et.al, Strategy for characterization of degradation products, Drug Test. Analysis, 2010, 2, 82–90.

Sumaia Araújo Pires et.al, LC-MS characterization of Valsartan degradation products, Brazilian J. of Pharma. Sci. vol. 51, n. 4, 2015, 839-845.




Fatal error: Call to a member function getGalleyLabel() on null in /home/innowar1/public_html/journals/cache/t_compile/%%38^38D^38D7420B%%article.tpl.php on line 189